EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. by Mu, Zhaomei et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medical Oncology Faculty Papers Department of Medical Oncology
1-1-2013
EZH2 knockdown suppresses the growth and
invasion of human inflammatory breast cancer cells.
Zhaomei Mu
Department of Medical Oncology, Thomas Jefferson University, Zhaomei.Mu@jefferson.edu
Hua Li
Fox Chase Cancer Center
Sandra V Fernandez
Department of Medical Oncology, Thomas Jefferson University, Sandra.Fernandez@jefferson.edu
Katherine R Alpaugh
Fox Chase Cancer Center
Rugang Zhang
Fox Chase Cancer Center
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/medoncfp
Part of the Oncology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Medical Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please
contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Mu, Zhaomei; Li, Hua; Fernandez, Sandra V; Alpaugh, Katherine R; Zhang, Rugang; and
Cristofanilli, Massimo, "EZH2 knockdown suppresses the growth and invasion of human
inflammatory breast cancer cells." (2013). Department of Medical Oncology Faculty Papers. Paper 25.
http://jdc.jefferson.edu/medoncfp/25
Authors
Zhaomei Mu, Hua Li, Sandra V Fernandez, Katherine R Alpaugh, Rugang Zhang, and Massimo Cristofanilli
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/medoncfp/25
RESEARCH Open Access
EZH2 knockdown suppresses the growth and
invasion of human inflammatory breast cancer
cells
Zhaomei Mu1,2†, Hua Li3†, Sandra V Fernandez1,2, Katherine R Alpaugh2, Rugang Zhang3 and
Massimo Cristofanilli1,2*
Abstract
Introduction: Inflammatory breast cancer (IBC) is the most metastatic variant of breast cancer with the poorest survival
in all types of breast cancer patients and presently therapeutic targets for IBC are very limited. Enhancer of zeste homolog
2 (EZH2) is frequently expressed in human IBC and its expression positively correlates with worse clinical outcome.
However, the molecular basis for EZH2 promoting IBC has not been explored. Here, we investigated the functional role of
EZH2 in IBC cells by examining the effects of its knockdown on the formation of tumor spheroids and invasion of these
cells in vitro and in vivo in an orthotopic xenograft model.
Methods: SUM149 and a new IBC cell line-FC-IBC-02 derived from pleural effusion fluid of an IBC patient were used in
this study. Specific knockdown of EZH2 was performed using short hairpin RNA (shRNA) specific to the human EZH2
gene. Cell growth and the formation of tumor spheroids were examined in vitro. The effects of EZH2 knockdown on IBC
cell migration and invasion were examined by a Boyden chamber assay. For the in vivo tumor growth studies, IBC cells
were orthotopically transplanted into the mammary fat pads of immunodeficient mice.
Results: The results showed that EZH2 is expressed at higher levels in human IBC cell lines compared with normal
human mammary epithelial cells, and the knockdown of EZH2 expression significantly suppressed cell growth and tumor
spheroid formation of human IBC cells in vitro. In addition, EZH2 knockdown inhibited the migration and invasion of IBC
cells. Significantly, EZH2 knockdown suppressed the angiogenesis and tumor growth of IBC cells in vivo.
Conclusions: Our results provide direct evidence that EZH2 is critical for the formation of tumor spheroids and invasion
of human IBC cells and could be a potential target for developing novel therapeutic strategies for
human IBC.
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Introduction
Inflammatory breast cancer (IBC) is the most aggressive
variant of locally advanced breast cancer, and currently ac-
counts for 1% to 6% of all breast cancer patients in the
United States [1,2]. IBC has shown the capacity to spread
early, primarily through lymphatic channels and secondar-
ily through blood vessels causing the specific inflammatory
signs, such as diffuse erythema, edema, tenderness, and
warmth [3,4]. IBC is difficult to detect as it does not
present as a lump but rather occurs as tumor emboli.
These IBC tumor emboli are non-adherent cell clusters
that rapidly spread by a continuous passive dissemination,
thus favoring both distal metastasis and local recurrence
[5]. Primary treatment of patients with IBC is typically
multimodal involving neoadjuvant combination chemo-
therapy followed by surgery, adjuvant chemotherapy, or
radiotherapy [6]. Epidermal growth factor receptor (EGFR)
and HER2 receptor overexpression have been demon-
strated as prognosis and predictive factors in IBC [7,8].
Anti-HER2 therapies have shown benefit in IBC patients
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with HER2 amplification, which accounts for approxi-
mately 40% of IBC [9]. However, therapeutic options for
patients with estrogen-receptor negative (ER-) and HER2
non-amplified IBC patients are very limited. Notably, IBCs
are predominantly basal-like or triple-negative as demon-
strated by the ER-negative, progesterone receptor (PgR)-
negative and HER2 non-amplified status [10]. Thus, there
is an urgent need to identify a new therapeutic strategy for
IBC, particularly for triple-negative IBC.
Enhancer of zeste homolog 2 (EZH2) is the catalytic
subunit of polycomb repressive complex 2 (PRC2), while
noncatalytic subunits suppressor of zeste 12 (SUZ12) and
embryonic ectoderm development (EED) are also neces-
sary for its optimal activity [11]. EZH2 is upregulated in
several types of cancers and has been implicated in re-
gulating multiple cellular processes such as proliferation,
differentiation, cell cycle, apoptosis, invasion, and self-
renewal [12,13]. For example, EZH2 is often expressed at
higher levels in breast cancer and its overexpression corre-
lates with aggressiveness and poor prognosis [14-20]. We
have recently shown that EZH2 is often expressed in IBCs
and is a marker for poor prognosis in these patients [21].
Interestingly, there is a significant positive correlation be-
tween EZH2 expression and triple-negative status [21].
Strikingly, all triple-negative tumors were found positive
for EZH2 expression. This expression pattern raises the
possibility that EZH2 could represent a potential thera-
peutic target in IBC and, in particular, in triple-negative
IBC that currently has very limited treatment options.
The clinical symptoms and biological features of IBC are
very distinct from other types of breast cancer. Currently
there are few human IBC cell lines available for studying
this complex disease. We have recently developed a new
IBC cell line FC-IBC-02 that was derived from the pleural
effusion fluid of a woman with metastatic secondary IBC
[22]. FC-IBC-02 cells are triple-negative, and form tumor
spheroids in suspension culture, a characteristic of cancer
stem cells, and recapitulate the tumor emboli, a signature
sign of IBC in humans in vivo xenograft models. FC-IBC-
02 cells also expressed some cancer stem cell (CSC)
markers. The CSC population is also thought to play a key
role in breast cancer development, progression, and relapse
following treatments [23-27]. Overexpression of EZH2
promotes self-renewal of breast tumor initiating cells [28].
Interestingly, in embryonic stem cells, EZH2 directly con-
trols the expression of Oct4, a stem cell marker, to regulate
the stem cell equilibrium [29]. Together, these evidences
suggest that EZH2 may regulate cancer stem/initiating cell
equilibrium in IBC.
In the present study, we examined the expression of
the components of PRC2 in human IBC cells, as well as
the effects of EZH2 knockdown on the formation of
tumor spheroids, invasion and tumor growth of human
IBC cells.
Methods and materials
Cell culture
SUM149 and SUM190 cells were cultured in Ham’s F-12
media supplemented with 10% fetal bovine serum (FBS),
1 μg/ml hydrocortisone, 5 μg/ml insulin and antibiotic-
antimycotic. Primary human mammary epithelial cells
(HMEC) were isolated and cultured as previously de-
scribed [30]. The protocol was approved by institutional
review board (IRB) of Fox Chase Cancer Center (FCCC).
The FC-IBC-02 tumor cells were derived from primary
human breast cancer cells isolated from pleural effusion
fluid of an IBC patient. Human samples used in this
study were acquired with approval of the Fox Chase
Cancer Center’s Institutional Review Board. Importantly,
written informed consent form was obtained from each
participant. FC-IBC-02 cells were cultured in Ham’s F12
with 10% FBS and 5 ml Insulin/L with 100 μg/L hydro-
cortisone and antibiotic-antimycotic. FC-IBC-02 cells
grow as both adherent (FC-IBC-02A) and suspension
(FC-IBC-02S) populations.
EZH2 knockdown and lentivirus infection
The sense sequences of 2 individual 21-nucleotide shRNAs
targeting the human EZH2 genes (shEZH2) were previ-
ously described [31]. Lentivirus packaging was performed
using ViraPower system (Invitrogen) according to the
manufacturer’s instruction as previously described [31].
Briefly, the cells were infected with lentivirus expressing
shEZH2 or vector control. The infected cells were drug
selected with 2 μg/mL of puromycin to eliminate non-
infected cells.
Antibodies and immunoblot
Immunoblot was performed using previously described
methods [31,32]. In brief, cells were lysed in 1 × lysis
buffer (Cell signaling) or 1 × SDS loading buffer. Tumor
tissue was homogenized in 10 mM Tris–HCl (pH 7.8),
the homogenate centrifuged at 10,000 rpm for 10 min
at 4°C, and glycerol added (final concentration 15%) to
the supernatant. Protein concentration was determined
using the BCA protein assay reagent kit (Pierce, Rock-
ford, IL). Equal amounts of protein from cell lysates or
tumor tissue homogenates were resolved by SDS-PAGE
electrophoresis. The membranes were incubated at 4°C
overnight with the following antibodies: mouse anti-
EZH2 (1:2,500; BD Bioscience), mouse anti-EED (1:2,000;
Millipore), mouse anti-SUZ12 [31], mouse anti-β-actin
(1:5,000; Santa Cruz). After incubation with anti-mouse
IgG horseradish peroxidase conjugated secondary anti-
body (1:5,000; Amersham Pharmacia Biotech), immu-
noreactive proteins were visualized by the enhanced
chemiluminescence reagents.
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Cell proliferation and tumor spheroid formation assays
Cells were infected with lentivirus encoding 2 individual
shEZH2s or control for 48 hrs. Cell proliferation was mon-
itored by absorbance using the MTS assay (CellTiter 96
AQueous One Solution cell proliferation assay, Promega)
according to the manufacturer’s instruction. 2000 cells
were seeded in triplicate in a 96-well plate. At the indi-
cated times, absorbance at 490 nm was measured in a
microplate reader.
For tumor spheroid formation, a total of 2000 single cell
suspensions were plated into 24-well ultra-low attachment
plates (Corning) and cultured in serum-free mamma-
ry epithelial growth medium (MEGM, BioWhittaker)
supplemented with B27 (Invitrogen), 20 ng/mL epidermal
growth factor (EGF), 40 ng/mL bFGF (BD Biosciences),
and 4 μg/mL heparin (Sigma) [22]. After 6 days in culture,
tumor spheroids were counted.
Cell migration and invasion assays
For cell migration assay, 48 hrs after shRNA infection,
SUM149 cells (7 × 104) were suspended in 0.5 ml of
Ham’s F-12 media and seeded onto the noncoated 8 μm
membrane of cell culture insert (BD Bioscences) in a 24
well plate with Ham’s F-12 media supplemented with
10% FBS. For matrigel invasion, the membrane of cell
culture insert was coated by adding 60 μl of 1:40 diluted
matrigel basement membrane matrix (BD Bioscences)
with Ham’s F-12 media. 1 × 105 cells were suspended in
0.5 ml of Ham’s F-12 media and plated on top of the
matrigel. After incubating 24 hrs, the cells were fixed
with 4% formaldehyde and stained with 0.5% crystal vio-
let in PBS. The number of cells that migrated across
the membrane or invaded through the matrigel-coated
membrane was determined in 9 fields across the center
and the periphery of the membrane.
In vivo tumorigenicity
The protocol was approved by FCCC institutional animal
care and use committee (IACUC). Control or shEZH2 ex-
pressing SUM149 (3 × 106, n = 6) and FC-IBC-02S (1 ×
106, n = 4) cells were suspended in 200 μL of 1:1 ratio of
phosphate-buffered saline/matrigel (BD Biosciences) and
orthotopically injected into the mammary fat pads of six
week old female C.B-17 severe combined immunodefi-
cient (SCID) mice. Tumor volume was calculated from
the formula TV = L*W*H*0.5236 where L, W, and H are
the tumor dimensions in three perpendicular dimensions
by caliper measurement. Mice were sacrificed 6 weeks
(SUM149) or 8 weeks (FC-IBC-02S) post inoculation. Tu-
mors were surgically removed and weighed.
For in vivo angiogenesis assay, formalin-fixed paraffin-
embedded tumors from shEZH2 or control groups were
cut onto glass slides and processed for immunohis-
tochemical (IHC) staining using previously described
methods [31]. Purified rat anti-mouse CD31 antibody
(BD PharMingen) was used for the staining. CD31-
positive vessels were enumerated in randomly selected
fields.
Statistical analysis
Quantitative data were expressed as mean ± SEM. Ana-
lysis of variance (ANOVA) with Student’s t test was used
to determine the significant differences among experi-
mental groups, and P < 0.05 was considered significant.
Results
EZH2 is expressed at higher levels in human IBC cells
EZH2 was expressed frequently in IBC tumors and pre-
dicts worse clinical outcome of IBC patients [21]. We first
sought to examine the expression of EZH2 and other es-
sential components of PRC2 namely EED, and SUZ12 in 3
individual isolations of normal primary HME cells and 3
human IBC cell lines. The SUM149 and SUM190 cell lines
are the only available human IBC cell lines that are widely
used in IBC studies. FC-IBC-02 cell line was a newly de-
rived IBC cell line using tumor cells from pleural effusion
fluid of a patient with metastatic secondary IBC [22]. FC-
IBC-02 cells were ER(−), Pgr(−) and HER2 non-amplified,
and formed tumor spheroids in suspension culture that
were strongly positive for E-cadherin, β-catenin adhesion
molecules. The tumors were developed with lung micro
metastasis when the cells were injected in the mammary
fat pad of SCID mice and recapitulated the tumor emboli
that is a signature of IBC in humans. Compared with nor-
mal HME cells, both EZH2 and SUZ12 were expressed at
significantly higher levels in all three tested human IBC cell
lines (Figure 1). Consistently, H3K27Me3, the product of
EZH2 histone H3 lysine 27 methyltransferase activity, was
also expressed at higher levels in IBC cell lines (Figure 1).
Interestingly, there was no obvious difference in EED pro-
tein expression between normal HMECs and human IBC
cell lines (Figure 1). Based on these results, we conclude
that EZH2, SUZ12, and H3K27Me3 are expressed at
higher levels in human IBC cells compared with normal
HMEC.
High tumorigenicity correlates with high expression of
EZH2 in FC-IBC-02 cells
We observed that the newly derived FC-IBC-02 tumor
cells grow as both adherent and suspension populations
when they are initially obtained from pleural effusion
fluid of the IBC patient. In addition, the suspension
population of FC-IBC-02 cells spontaneously formed
tumor spheroids, a characteristic of tumor stem/initiat-
ing cells (Figure 2A). When single cells were cultured in
suspension under low adherence conditions, adherent
cells formed less and smaller tumor spheroids compared
to suspension cells (Figure 2B), suggesting that adherent
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cells are unable to self-renew. EZH2 has been implicated
in regulating stem cell renewal, differentiation, and car-
cinogenesis [28,29]. Thus, we compared the expression of
EZH2 in the initial adherent and suspension populations
of FC-IBC-02 cells. Interestingly, the expression level of
EZH2 was higher in suspension cell populations compared
to adherent cell populations (Figure 2C). Next, we ortho-
topically transplanted the equal numbers (2 × 106) of
adherent and suspension FC-IBC-02 cells into the mam-
mary fat pads of mice with 5 mice in each cell population.
Tumor volume was monitored over time, and the tumor
was excised and weighed after 7 weeks. Interestingly, the
tumors were notably smaller from the transplanted adher-
ent cell populations compared with suspension populations
(Figure 2D). Together, our results suggest that expression
levels of EZH2 positively correlates with tumor spheroid
formation and tumorigenicity in this new IBC cell line.
Knockdown of EZH2 inhibits the tumor spheroid formation
of human IBC cells in vitro and tumor growth in vivo
Since EZH2 was overexpressed in IBC cells and EZH2 ex-
pression positively correlates with tumor spheroid growth
and tumorigenicity in FC-IBC-02 cells, we sought to deter-
mine the effects of EZH2 knockdown on tumor spheroid
formation of IBC cells in vitro and the tumorigenicity of
IBC in vivo in an orthotopic xenograft model in immuno-
deficient mice. To knockdown EZH2 expression in FC-IBC-
02S and SUM149 cells, we used 2 individual shRNAs to the
human EZH2 gene (shEZH2). We first confirmed the
knockdown efficacy of these shEZH2s in human IBC cell
lines by immunoblotting (Figure 3A). Consistently, the level
of H3K27Me3 expression was also significantly reduced by
β-actin
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EED
H3K27Me3
EZH2
Figure 1 EZH2 is expressed at higher levels in human IBC cell
lines. Expression of EZH2, SUZ12, EED, H3K27Me3, and β-actin in 3
indicated human IBC cell lines and 3 individual batches of primary
normal human mammary epithelial cell cultures (HMEC) was
examined by immunoblot analysis.
A D
0
50
100
150
200
250
300
350
400
FC-IBC-02S
FC-IBC-02A
p < 0.001 
Tu
m
o
r 
w
ei
gh
t  
(m
g)
0
50
100
150
200
250 FC-IBC-02A
FC-IBC-02S
Tu
m
o
r 
v
o
lu
m
e 
(m
m
3 ) 
3             4              5              6             7
*
FC-IBC-02AFC-IBC-02S
FC-IBC-02AFC-IBC-02SB
EZH2
-actin
C
β
Figure 2 High tumorigenicity correlates with high expression of EZH2 in FC-IBC-02 cells. A. Initial FC-IBC-02 cells obtained from pleural
effusion fluid of IBC patient growing as suspension (FC-IBC-02S) and adherent (FC-IBC-02A) populations (×200 magnification). Tumor spheroids
exhibit budding from parent to daughter spheroid in suspension culture. B. Tumor spheroid growth of FC-IBC-02S and FC-IBC-02A cells in
suspensions under ultra-low attachment culture condition for 6 days (×100 magnification). C. Expression of EZH2 in suspension and adherent
populations of FC-IBC-02 cells was examined by immunoblot. D. Growth of FC-IBC-02 adherent (2 × 106) and suspension (2 × 106) cells in vivo in
SCID mice. Tumor volume was monitored over time, and the tumor was excised and weighed after 7 weeks. *, P < 0.001 compared to FC-IBC-02A
at week 7.
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shEZH2 in both cell lines (Figure 3A). We compared the
cell growth of control and shEZH2-infected IBC cells using
the MTS assay. Compared with controls, EZH2 knockdown
significantly suppressed the growth of human IBC cells
(Figure 3C and D). We observed the growth inhibition by
two individual shEZH2s, suggesting that the observed ef-
fects are likely not due to off-target effects. In addition,
shEZH2 suppressed the growth of both SUM149 (Figure 3C)
and FC-IBC-02S (Figure 3D) IBC cell lines, suggesting
that the observed effects are not cell line specific. Im-
portantly, we showed EZH2 knockdown significantly sup-
pressed the tumor spheroid formation of FC-IBC-02S cells
in suspension culture under ultra-low attachment culture
condition, which is a characteristic of IBC cancer stem
cells (Figure 3B). Based on these results, we conclude that
knockdown of EZH2 suppresses the proliferation and
tumor spheroid growth of human IBC cells in vitro.
We next sought to determine the effects of EZH2 knock-
down on the tumorigenicity of human IBC cells in vivo in
an orthotopic xenograft model in immunodeficient mice.
Toward this goal, control and shEZH2-expressing FC-IBC-
02S and SUM149 cells were orthotopically transplanted into
the mammary fat pads of immunodeficient mice. Compared
with controls, shEZH2 significantly suppressed the growth
of xenografted human IBC cells in immunodeficient mice.
Similar suppression of tumor growth by shEZH2 was ob-
served for both xenografted FC-IBC-02S (Figure 4A and C)
and SUM149 (Figure 4B and D) IBC cells, suggesting that
the observed effects are not cell line specific. We confirmed
the EZH2 knockdown in dissected tumors by immuno-
blotting (Figure 4E and F). Together, we conclude that
EZH2 knockdown significantly inhibits the growth of hu-
man IBC cells in vivo in orthotopic xenograft IBC models.
EZH2 knockdown inhibits the invasion and tumor
angiogenesis of human IBC cells
EZH2 has been implicated in regulating invasion of
breast cancer cells [15]. Thus, we sought to determine
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Figure 3 EZH2 knockdown inhibits the cell growth of SUM149 and FC-IBC-02S cells and tumor spheroid formation of FC-IBC-02S cells.
A. SUM149 and FC-IBC-02S cells were infected with 2 individual lentivirus encoded shEZH2 or control. Expression of EZH2, H3K27Me3, H3K9Me3,
and histone H3 was examined in drug-selected cells by western blotting. B. Same as A, 2000 of control or shEZH2 expressing FC-IBC-02S single
cells were cultured in suspension in ultra-low attachment plates. After culturing 6 days, the number of tumor spheroids was counted. Mean of 3
independent experiments with SEM. *, P < 0.001 compared to control. C and D. Same as A, but 2 × 103 of drug-selected cells were seeded and
assayed by MTS in SUM149 (C) and FC-IBC-02S (D) cells at indicated time points. Mean of 3 independent experiments with SEM. *, P < 0.01
compared to control.
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the effects of EZH2 knockdown on the invasion of human
IBC cells. Toward this goal, we tested the ability of human
IBC cells infected with control or shEZH2-encoding lenti-
virus migrating through uncoated membrane or invading
through matrigel-coated membrane using a Boyden-
chamber invasion assay. Compared with controls, EZH2
knockdown significantly inhibited the migration and inva-
sion of SUM149 cells (Figure 5A and B). We conclude that
EZH2 knockdown inhibits the migration and invasion of
human IBC cells. Interestingly, EZH2 knockdown tumors
showed less blood vessels compared with control tumors
(Figure 4A and B). To examine the reduced angiogenesis,
we immunostained tumor sections from xenografted FC-
IBC-02S with CD31, a marker used to quantitate vessel
density. Compared with control tumors, EZH2 knock-
down tumors displayed a significant reduction in CD31-
positive vessels (Figure 5C). These results suggest that
EZH2 knockdown inhibits tumor angiogenesis, and subse-
quently inhibits tumor growth.
Discussion
The major finding of this study is that the EZH2 knock-
down significantly suppressed the formation of tumor
spheroids in vitro (a characteristic of IBC cancer stem
cells), and tumor growth in vivo in a new human IBC
model. New FC-IBC-02 cell line is the first to be used in
studying the functional role of EZH2, although the nega-
tive effects of silencing of EZH2 on cell growth have
been shown in some breast cancer cell lines including
SUM149 cells.
We have recently shown that EZH2 is often expressed
in IBC tumors and is associated not only with unfavor-
able prognostic variables but also with significantly
worsening survival [21]. Consistent with previous find-
ings, EZH2 was overexpressed in human IBC cell lines.
These findings suggest that clinical outcomes of IBC pa-
tients can be stratified on the basis of EZH2 status. We
further examined the function of EZH2 in SUM149 cells
and a new IBC cell line-FC-IBC-02 derived from pleural
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Figure 4 EZH2 knockdown inhibits the growth of SUM149 and FC-IBC-02S cells in vivo in SCID mice. A and B. Control or shEZH2
expressing FC-IBC-02S (1 × 106) and SUM149 (3 × 106) cells were orthotopically transplanted into the mammary fat pads of SCID mice.
Nine weeks (FC-IBC-02S cells) and six weeks (SUM149 cells) post injection, tumors were removed from mice and imaged. C (FC-IBC-02S) and
D (SUN149) cells, tumor size was measured by caliper measurements. Data shown represent mean tumor volume with SEM, p value compared
with control. E (FC-IBC-02S) and F (SUN149), western blot assay of EZH2 expression from pooled FC-IBC-02S and SUM149 xenografted tumors.
Mu et al. Journal of Experimental & Clinical Cancer Research 2013, 32:70 Page 6 of 9
http://www.jeccr.com/content/32/1/70
effusion fluid of an IBC patient. A very recent study
showed that SUM149 cell line might not be IBC-specific
from gene expression data [33]. FC-IBC-02 cell line,
however, is a more representative model for the IBC
studies [22]. The treatment options for IBC patients,
particularly for triple-negative IBC are very limited at
present, while the results of this study indicate that
EZH2 is a putative target for developing a new treatment
for this devastating disease.
The mechanism of EZH2 promoting IBC remains to be
elucidated. With IBC human cell lines in this study, we
showed that both EZH2 and H3K27Me3 are expressed at
higher levels compared to cultured normal HME cells
(Figure 1). EZH2 catalyzes trimethylation of lysine 27 on
histone 3, an epigenetic label mediating gene silencing,
while the correlation between H3K27Me3 expression and
clinical outcome is inconsistent. A very recent study
showed that there was a significantly different expression
of both EZH2 and H3K27Me3 in different subtypes of
breast tumor [34]. High abundance of EZH2 was detected
in basal-like, triple-negative and HER2-enriched tumors,
but high H3K27Me3 was found mainly in luminal A,
HER2-enriched and normal-like tumors. Further studies
are warranted to determine the role of H3K27Me3 expres-
sion in IBC tumors.
Although there are few cell lines currently available to
evaluate the biology of IBC, there is no good model
available for CSC studies in IBC. The majority of IBC
studies have been performed using the cell lines
SUM149 and SUM 190, both of which were developed
from the primary tumor of IBC patients [10]. Only the
Mary-X and the WIBC-9 in vivo xenograft models are
available to recapitulate the tumor emboli that are the
signature of IBC in humans, but none of them can be
successfully passaged or propagated long term in vitro
cultures [35,36]. Our recent studies have shown that
new developed FC-IBC-02 cells can be successfully pas-
saged under both adherent and suspension culture con-
ditions [22]. This new IBC model could be a more
representative model for the further IBC studies since
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Figure 5 EZH2 knockdown suppresses the invasion and tumor angiogenesis of human IBC cells. A. Control and shEZH2 expressing
SUM149 cells at equal number were seeded onto the noncoated membrane (migration) and matrigel-coated membrane (invasion). After
incubating 24 hrs, the cells migrated through both uncoated and matrigel-coated membrane were stained with 0.05% crystal violet in PBS.
B. Quantitation of A, relative percentage of shEZH2 expressing cells migrated through uncoated membrane or invaded through matrigel-coated
membrane compared to controls was indicated. Mean of 3 independent experiments with SEM. *, P < 0.05 compared to control. C. Tumor tissues
from FC-IBC-02S xenografts were stained with anti-CD31 antibody to measure microvessel density (×100 magnification). The CD31-positive
microvessels are marked (arrows). Quantitation of CD31 vessel staining is shown in the bottom graph. *, P < 0.01 compared to control.
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FC-IBC-02 cells were able to develop tumor with the
presence of tumor emboli and metastasis in SCID mice.
In this study, we are interested in studying the functional
role of EZH2 in this new IBC model. We observed that
newly derived FC-IBC-02 suspension cell population
formed tumor spheroids, a characteristic of CSC and
expressed a higher level of EZH2 and generated larger
tumor in size compared to initial adherent cell popula-
tion when transplanted into the mammary fat pads of
SCID mice (Figure 2D). Notably, knockdown of EZH2
significantly inhibits the tumor spheroid growth of hu-
man IBC cells in vitro. Recent studies showed that CSC
population may be responsible for resistance to chemo-
therapy, radiation therapy and contribute to relapse fol-
lowing the treatment [25-27,37,38]. This suggests that
more effective therapies will require the successful
targeting of the CSCs population. We believe that the
FC-IBC-02 cell line described in this study could serve
as a potential model for CSC studies in human IBC. The
findings of this study provide evidence that EZH2 is a
potential target for the self-renewal of IBC cells.
Angiogenesis is required for invasive tumor growth
and metastasis. A recent study showed that EZH2
is a key regulator of tumor angiogenesis through its
expression in cancer associated endothelial cells in hu-
man ovarian cancer [39]. Interestingly, we observed a
visible evidence for the loss of angiogenesis in the EZH2
knockdown tumors (Figure 4A and B). In addition, there
was a significant reduction in CD31-positive vessels in
EZH2 knockdown tumors compared to control tumors
(Figure 5C), suggesting that the loss of angiogenesis sub-
sequently inhibits tumor growth. The mechanisms im-
plicated in the angiogenesis role of EZH2 in IBC need
further investigation. Several specific inhibitors of
EZH2’s methyltransferase activity have been reported
[40-42]. Our recent studies have shown that the three-
dimensional culture sensitizes epithelial ovarian cancer
cells to EZH2 methyltransferase inhibition, which sup-
presses cell growth, induces apoptosis and inhibits inva-
sion [43]. Further studies are warranted to examine the
effects of these specific inhibitors of EZH2 on the char-
acteristics of IBC, such as homotypic aggregation of
tumor emboli, invasion and metastasis of IBCs.
Conclusions
EZH2 are overexpressed in human IBC cell lines. EZH2 is
critical for the formation of tumor spheroids and invasion
of human IBC cells and could be a potential target for de-
veloping novel therapeutic strategies for human IBC.
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